vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与null（SWIM）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是null的1.5倍（$152.6M vs $100.0M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs -7.0%，领先41.5%），null同比增速更快（14.5% vs 7.6%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $14.1M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs -4.9%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
该企业是一家源自美国的跨国律师事务所，1934年创立于加利福尼亚州洛杉矶，在诉讼业务、公司法务以及监管合规法律领域拥有深厚的行业积累与知名度，是全球颇具影响力的综合性律所之一。
CPRX vs SWIM — 直观对比
营收规模更大
CPRX
是对方的1.5倍
$100.0M
营收增速更快
SWIM
高出6.9%
7.6%
净利率更高
CPRX
高出41.5%
-7.0%
自由现金流更多
CPRX
多$30.8M
$14.1M
两年增速更快
CPRX
近两年复合增速
-4.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $100.0M |
| 净利润 | $52.7M | $-7.0M |
| 毛利率 | 82.9% | 28.0% |
| 营业利润率 | 40.5% | -10.7% |
| 净利率 | 34.5% | -7.0% |
| 营收同比 | 7.6% | 14.5% |
| 净利润同比 | -5.8% | 76.0% |
| 每股收益（稀释后） | $0.40 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRXSWIM
| Q4 25 | $152.6M | $100.0M | ||
| Q3 25 | $148.4M | $161.9M | ||
| Q2 25 | $146.6M | $172.6M | ||
| Q1 25 | $141.4M | $111.4M | ||
| Q4 24 | $141.8M | $87.3M | ||
| Q3 24 | $128.7M | $150.5M | ||
| Q2 24 | $122.7M | $160.1M | ||
| Q1 24 | $98.5M | $110.6M |
净利润CPRXSWIM
| Q4 25 | $52.7M | $-7.0M | ||
| Q3 25 | $52.8M | $8.1M | ||
| Q2 25 | $52.1M | $16.0M | ||
| Q1 25 | $56.7M | $-6.0M | ||
| Q4 24 | $55.9M | $-29.2M | ||
| Q3 24 | $43.9M | $5.9M | ||
| Q2 24 | $40.8M | $13.3M | ||
| Q1 24 | $23.3M | $-7.9M |
毛利率CPRXSWIM
| Q4 25 | 82.9% | 28.0% | ||
| Q3 25 | 84.7% | 35.4% | ||
| Q2 25 | 85.9% | 37.1% | ||
| Q1 25 | 87.3% | 29.5% | ||
| Q4 24 | 84.7% | 24.6% | ||
| Q3 24 | 85.0% | 32.4% | ||
| Q2 24 | 87.4% | 33.1% | ||
| Q1 24 | 87.3% | 27.7% |
营业利润率CPRXSWIM
| Q4 25 | 40.5% | -10.7% | ||
| Q3 25 | 44.7% | 13.3% | ||
| Q2 25 | 45.2% | 14.3% | ||
| Q1 25 | 44.8% | -4.4% | ||
| Q4 24 | 44.3% | -14.9% | ||
| Q3 24 | 39.6% | 8.9% | ||
| Q2 24 | 44.2% | 12.5% | ||
| Q1 24 | 27.5% | -1.9% |
净利率CPRXSWIM
| Q4 25 | 34.5% | -7.0% | ||
| Q3 25 | 35.6% | 5.0% | ||
| Q2 25 | 35.6% | 9.3% | ||
| Q1 25 | 40.1% | -5.4% | ||
| Q4 24 | 39.4% | -33.4% | ||
| Q3 24 | 34.1% | 3.9% | ||
| Q2 24 | 33.2% | 8.3% | ||
| Q1 24 | 23.6% | -7.1% |
每股收益（稀释后）CPRXSWIM
| Q4 25 | $0.40 | $-0.06 | ||
| Q3 25 | $0.42 | $0.07 | ||
| Q2 25 | $0.41 | $0.13 | ||
| Q1 25 | $0.45 | $-0.05 | ||
| Q4 24 | $0.44 | $-0.24 | ||
| Q3 24 | $0.35 | $0.05 | ||
| Q2 24 | $0.33 | $0.11 | ||
| Q1 24 | $0.19 | $-0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | — |
| 总债务越低越好 | — | $279.8M |
| 股东权益账面价值 | $954.3M | $405.9M |
| 总资产 | $1.1B | $823.2M |
| 负债/权益比越低杠杆越低 | — | 0.69× |
8季度趋势，按日历期对齐
现金及短期投资CPRXSWIM
| Q4 25 | $709.2M | — | ||
| Q3 25 | $689.9M | — | ||
| Q2 25 | $652.8M | — | ||
| Q1 25 | $580.7M | — | ||
| Q4 24 | $517.6M | — | ||
| Q3 24 | $442.3M | — | ||
| Q2 24 | $375.7M | — | ||
| Q1 24 | $310.4M | — |
总债务CPRXSWIM
| Q4 25 | — | $279.8M | ||
| Q3 25 | — | $281.1M | ||
| Q2 25 | — | $281.5M | ||
| Q1 25 | — | $306.9M | ||
| Q4 24 | — | $281.5M | ||
| Q3 24 | — | $282.8M | ||
| Q2 24 | — | $282.4M | ||
| Q1 24 | — | $282.8M |
股东权益CPRXSWIM
| Q4 25 | $954.3M | $405.9M | ||
| Q3 25 | $920.2M | $408.4M | ||
| Q2 25 | $856.0M | $398.4M | ||
| Q1 25 | $794.3M | $381.1M | ||
| Q4 24 | $727.6M | $387.2M | ||
| Q3 24 | $660.9M | $416.6M | ||
| Q2 24 | $608.7M | $408.1M | ||
| Q1 24 | $561.4M | $391.8M |
总资产CPRXSWIM
| Q4 25 | $1.1B | $823.2M | ||
| Q3 25 | $1.1B | $844.4M | ||
| Q2 25 | $971.9M | $822.1M | ||
| Q1 25 | $908.9M | $824.6M | ||
| Q4 24 | $851.4M | $794.2M | ||
| Q3 24 | $772.0M | $853.4M | ||
| Q2 24 | $706.4M | $830.0M | ||
| Q1 24 | $646.7M | $808.6M |
负债/权益比CPRXSWIM
| Q4 25 | — | 0.69× | ||
| Q3 25 | — | 0.69× | ||
| Q2 25 | — | 0.71× | ||
| Q1 25 | — | 0.81× | ||
| Q4 24 | — | 0.73× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.69× | ||
| Q1 24 | — | 0.72× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $23.3M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $14.1M |
| 自由现金流率自由现金流/营收 | 29.4% | 14.1% |
| 资本支出强度资本支出/营收 | 0.0% | 9.2% |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | $38.0M |
8季度趋势，按日历期对齐
经营现金流CPRXSWIM
| Q4 25 | $44.9M | $23.3M | ||
| Q3 25 | $32.4M | $51.0M | ||
| Q2 25 | $71.3M | $36.0M | ||
| Q1 25 | $60.0M | $-46.9M | ||
| Q4 24 | $70.9M | $6.2M | ||
| Q3 24 | $72.9M | $37.2M | ||
| Q2 24 | $64.1M | $52.4M | ||
| Q1 24 | $31.9M | $-34.5M |
自由现金流CPRXSWIM
| Q4 25 | $44.9M | $14.1M | ||
| Q3 25 | — | $45.2M | ||
| Q2 25 | $71.3M | $29.1M | ||
| Q1 25 | — | $-50.3M | ||
| Q4 24 | $70.8M | $-98.0K | ||
| Q3 24 | $72.6M | $33.2M | ||
| Q2 24 | $64.1M | $47.9M | ||
| Q1 24 | $31.7M | $-39.9M |
自由现金流率CPRXSWIM
| Q4 25 | 29.4% | 14.1% | ||
| Q3 25 | — | 27.9% | ||
| Q2 25 | 48.6% | 16.8% | ||
| Q1 25 | — | -45.2% | ||
| Q4 24 | 49.9% | -0.1% | ||
| Q3 24 | 56.4% | 22.1% | ||
| Q2 24 | 52.3% | 29.9% | ||
| Q1 24 | 32.2% | -36.0% |
资本支出强度CPRXSWIM
| Q4 25 | 0.0% | 9.2% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 4.0% | ||
| Q1 25 | 0.0% | 3.1% | ||
| Q4 24 | 0.1% | 7.2% | ||
| Q3 24 | 0.2% | 2.7% | ||
| Q2 24 | 0.0% | 2.8% | ||
| Q1 24 | 0.2% | 4.8% |
现金转化率CPRXSWIM
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | 6.29× | ||
| Q2 25 | 1.37× | 2.25× | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | 6.32× | ||
| Q2 24 | 1.57× | 3.95× | ||
| Q1 24 | 1.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
SWIM
| In Ground Swimming Pools | $50.2M | 50% |
| Covers | $37.0M | 37% |
| Liners | $12.7M | 13% |
